Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Genprex, Inc. (NASDAQ: GNPX).

Full DD Report for GNPX

You must become a subscriber to view this report.


Recent News from (NASDAQ: GNPX)

Midday Gainers / Losers (05/14/2018)
Gainers:  IMTE +59% . GALT +29% . EOLS +24% . BOXL +21% . AST +21% . TNDM +18% . CLWT +17% . FRED +17% . ASCMA +16% . MYO +16% . More news on: Integrated Media Technology Limited, Galectin Therapeutics, Inc., Evolus, Inc., Stocks on the move, , Read...
Source: SeekingAlpha
Date: May, 14 2018 12:46
Keeping It Simple On The Short Side
Welcome to Editor's Notes! I aim to sort through the ideas we publish each day and highlight a few that may be of interest to readers, along with comments that may add a helpful gloss. If you have thoughts, comment below or send me a direct message and let me know what you think. Your fe...
Source: SeekingAlpha
Date: May, 11 2018 13:20
We Believe Genprex Is A Disaster In The Making
Overview Genprex ( GNPX ) is a newly-listed company with only 4 full-time employees that describes itself as “a clinical stage gene therapy company developing a new approach to treating cancer.” Despite the supposed “new approach” to cancer treatment, we l...
Source: SeekingAlpha
Date: May, 09 2018 11:30
Genprex Selects Accenture To Support Acceleration Of Oncoprex Clinical Development Program
AUSTIN, Texas and CAMBRIDGE, Mass. , May 8, 2018 /PRNewswire/ --  Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has selected Accenture to provide clinical data ma...
Source: PR Newswire
Date: May, 08 2018 08:00
Genprex To Present At 2018 Disruptive Growth & Healthcare Conference
AUSTIN, Texas , May 7, 2018 /PRNewswire/ --  Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that Rodney Varner , Chairman and CEO, will present at t...
Source: PR Newswire
Date: May, 07 2018 08:05
Genprex Announces $10 Million Private Placement
AUSTIN, Texas , May 7, 2018 /PRNewswire/ --  Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it has entered into definitive securities purchase a...
Source: PR Newswire
Date: May, 07 2018 08:00
Premarket Losers as of 9:05 am (5/1/2018)
IVAC   -24%  on Q1 earnings . More news on: Intevac, Inc., CommScope Holding Company Inc., Cognex Corporation, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 01 2018 09:13
Premarket Gainers as of 9:05 am (04/30/2018)
STDY +81%  on acquisition by United Therapeutics for up to $216M. More news on: SteadyMed, Pluristem Therapeutics, Inc., Andeavor, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: April, 30 2018 09:27
Midday Gainers / Losers (04/27/2018)
Gainers : GNPX +36% . ENVA +27% . BOOM +24% . AQMS +20% . CYAD +19% . NVIV +17% . SIVB +16% . EHTH +16% . AQB +15% . KN +15% . More news on: Genprex, Inc, Enova International, Inc., DMC Global Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: April, 27 2018 12:45
Genprex up 87%
Recent IPO Genprex ( GNPX +86.8% ), a gene therapy developer, is up big on a whopping 43x surge in volume. Shares have more than doubled from the $5 debut price. More news on: Genprex, Inc, Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: April, 26 2018 15:10

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1711.9011.5912.668610.56264,716

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-214,99713,61336.7076Short
2018-08-208,50513,01165.3678Short
2018-08-176,54322,70228.8212Cover
2018-08-1625,40331,17881.4773Short
2018-08-158,32910,71777.7176Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GNPX.


About Genprex, Inc. (NASDAQ: GNPX)

Logo for Genprex, Inc. (NASDAQ: GNPX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: GNPX)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 15 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 10 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: April, 27 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: April, 17 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 16 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 11 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 04 2018
      Notification that form 10-K will be submitted late
      Filing Type: NT 10-KFiling Source: edgar
      Filing Date: April, 03 2018
      Post-effective amendment filed solely to add exhibits to a registration statement
      Filing Type: POS EXFiling Source: edgar
      Filing Date: March, 29 2018

       

       


      Daily Technical Chart for (NASDAQ: GNPX)

      Daily Technical Chart for (NASDAQ: GNPX)


      Stay tuned for daily updates and more on (NASDAQ: GNPX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: GNPX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GNPX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of GNPX and does not buy, sell, or trade any shares of GNPX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/